Current systemic treatment options and new developments in palliative first-line treatment of head and neck squamous cell carcinoma

被引：0
作者：
Florian Kocher
Andreas Seeber
机构：
[1] Medical University of Innsbruck,Department of Internal Medicine V (Hematology and Oncology), Comprehensive Cancer Center Innsbruck
来源：
memo - Magazine of European Medical Oncology | 2023年 / 16卷
关键词：
Head and neck squamous cell carcinoma (HNSCC); Palliative first-line tratment; Recent trials; Treatment algorithm;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
This short review gives an overview of current treatment concepts, recently published trials, and novel developments in relapsed or metastatic head and neck squamous cell carcinoma (HNSCC) not amendable for local curative treatment. Trials with potential future clinical implications and relevant updates of landmark trials are provided as well.
引用
收藏
页码：176 / 179
页数：3
相关论文
共 107 条
  • [1] Machiels JP(2020)Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 31 1462-1475
  • [2] Leemans RC(2019)Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Lancet 394 1915-1928
  • [3] Golusinski W(2022)Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048 Ann Oncol 33 S295-S322
  • [4] Grau C(2023)Nivolumab plus Ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: the final results of checkmate 651 J Clin Oncol 41 2166-2180
  • [5] Licitra L(2023)Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study Ann Oncol 34 262-274
  • [6] Gregoire V(2008)Platinum-based chemotherapy plus cetuximab in head and neck cancer N Engl J Med 359 1116-1127
  • [7] Burtness B(2014)Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice Anticancer Res 34 1531-1535
  • [8] Harrington KJ(2013)Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD Cancer Genomics Proteomics 10 89-92
  • [9] Greil R(2005)Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group J Clin Oncol 23 3562-3567
  • [10] Soulières D(2022)Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study Ann Oncol 33 S839-S840
12345678910